Mutated in TGFβR2 is predictive of resistance to ICB in non-small-cell lung cancer (NSCLC), but there are currently limited reports concerning the prognostic significance of TGFβR2 mutations in the context of CRC [183]. This evidence concerns the gene TGFBR2 and colorectal carcinoma.